Scinai Immunotherapeutics (SCNI) Total Non-Current Liabilities (2017 - 2026)

Scinai Immunotherapeutics has reported Total Non-Current Liabilities for 10 years, with the latest figure at $3.1 million in Q1 2026.

• Quarterly Total Non-Current Liabilities changed N/A year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (changed N/A YoY) and the FY2025 annual result came in at $1.9 million, up 16.4% from the prior year.
• Total Non-Current Liabilities rose to $3.1 million in Q1 2026 per SCNI's latest filing, from $1.9 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $26.5 million in Q4 2022 and troughed at $866000.0 in Q3 2024.
• A 5-year average of $14.3 million and a median of $18.4 million in 2022 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities soared 734.22% in 2022, then slumped 95.61% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $26.5 million in 2022, then dropped by 23.51% to $20.3 million in 2023, then slumped by 91.78% to $1.7 million in 2024, then gained by 16.4% to $1.9 million in 2025, then jumped by 62.13% to $3.1 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $3.1 million, $1.9 million, and $1.9 million for Q1 2026, Q4 2025, and Q2 2025 respectively.